Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial

• Published in: Acta diabetologica 2017-05, Vol.54 (5), p.499-507
• Main Authors: Bo, S., Ponzo, V., Evangelista, A., Ciccone, G., Goitre, I., Saba, F., Procopio, M., Cassader, M., Gambino, R.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antioxidants; Antioxidants - administration & dosage; C-Reactive Protein - metabolism; Clinical trials; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Original Article; Polyphenols; Serum Amyloid P-Component - metabolism; Stilbenes - administration & dosage; Treatment Outcome
• ISSN: 0940-5429; 1432-5233
• DOI: 10.1007/s00592-017-0977-y

Aims The anti-inflammatory effects of the polyphenol resveratrol in patients with type 2 diabetes mellitus (T2DM) are controversial. Its role on pentraxin 3 (PTX3) concentrations, a human acute phase protein, has never been evaluated. Our aim was to determine whether a two-dosage resveratrol supplementation (500 and 40 mg/day) has an impact on PTX3 values in T2DM patients from a double-blind randomized placebo-controlled trial. Variations in total antioxidant status (TAS) were evaluated too. Methods A total of 192 T2DM patients were randomized to receive resveratrol 500 mg/day (Resv 500 arm), resveratrol 40 mg/day (Resv 40 arm) or placebo for 6 months. At baseline and at the trial end, PTX3 and TAS values were determined. Results A dose-dependent increase in PTX3 concentrations of 4.7% (Resv 40 arm) and 26.3% (Resv 500 arm), and 8.0% reduction after placebo were found. Adjusted mean differences of change versus placebo were 0.16 (95% CI 0.01–0.32) and 0.25 (0.09–0.42) in the Resv 40 and Resv 500 arms, respectively. At subgroup analyses, lower diabetes duration, aspirin, alcohol use, younger age, female gender, smoking (Resv 500 arm) and female gender and aspirin use (Resv 40 arm) were associated with higher PTX3 increments. A dose-dependent increment in TAS values in the resveratrol arms (1.4 and 6.4% for Resv 40 and Resv 500, respectively), and a reduction in placebo arm (−8.9%) were observed. Adjusted mean differences of change were 28.5 (95% CI 10.1–46.8) and 44.8 (25.4–64.1) in the Resv 40 and Resv 500 arms, respectively. Conclusion Resveratrol supplementation increased PTX3 and TAS levels in a dose-dependent manner in T2DM patients. At present, potential clinical implications of these results remain unclear. ClinicalTrials.gov Identifier NCT02244879.